Lilly’s Arxxant Granted Priority Review For Diabetic Retinopathy
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trials are ongoing for additional indications for the protein kinase C-beta inhibitor ruboxistaurin.